TradeFlare's AI research teams analysed ABCL on 25 market nights between May 7, 2026 and October 13, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 13, 2026 | HOLD | $12.64 | — / — | not yet | not yet | The current market regime and stock-specific factors do not support a directional trade. |
| October 12, 2026 | HOLD | $12.55 | $15.70 / $10.67 | not yet | not yet | The stock is currently in a neutral market regime with a bearish fundamental outlook and high risk, making it unsuitable for a buy recommendation. |
| October 9, 2026 | HOLD | $12.02 | — / — | not yet | not yet | The stock is currently in a neutral market environment, and ABCL's mixed technical signals and high risk profile warrant a cautious approach. |
| September 1, 2026 | HOLD | $11.48 | — / — | -2.0% | +29.3% | Positive clinical trial results for drug candidates. |
| August 31, 2026 | BUY | $11.35 | $14.19 / $9.65 | -0.3% | +29.1% | The technical setup suggests an immediate upward move, but the fundamental and risk profiles warrant a shorter-term outlook. |
| August 28, 2026 | BUY | $12.40 | $15.50 / $10.54 | +0.7% | +22.6% | The bullish technical trend and fundamental outlook suggest a medium-term upward move. |
| August 27, 2026 | HOLD | $12.24 | — / — | -6.7% | +2.4% | The current market regime is neutral, and while ABCL has bullish technicals and sentiment, its neutral fundamental outlook and high risk score, combined with the market conditions, warrant a cautious |
| August 26, 2026 | BUY | $12.50 | $15.63 / $10.63 | -7.2% | +3.4% | The technical uptrend and positive sentiment suggest a short-to-medium term upward move. |
| August 25, 2026 | BUY | $10.61 | $13.79 / $9.02 | -9.8% | -1.5% | The technical setup suggests a potential breakout, and the fundamental and sentiment teams are bullish, indicating a medium-term upward trend. |
| August 24, 2026 | BUY | $11.32 | $15.75 / $8.93 | +8.2% | +19.2% | The technical setup and insider buying suggest a near-term upward move, but the fundamental risks warrant a shorter time horizon. |
| August 18, 2026 | BUY | $11.20 | $14.56 / $9.52 | +12.4% | +5.0% | The post-earnings drift signal suggests momentum will continue for several weeks. |
| August 17, 2026 | BUY | $11.38 | $13.13 / $8.59 | -5.3% | +1.9% | The post-earnings drift signal suggests a sustained upward move over the coming weeks. |
| August 14, 2026 | BUY | $10.97 | $14.82 / $9.32 | -0.5% | -1.9% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| August 13, 2026 | BUY | $10.35 | $13.46 / $8.80 | +5.5% | -0.7% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| June 17, 2026 | BUY | $5.09 | — / — | +22.4% | +18.8% | Positive Phase 1 data for ABCL635. |
| June 16, 2026 | BUY | $5.26 | — / — | +18.5% | +21.0% | Encouraging clinical trial data for ABCL635. |
| June 1, 2026 | BUY | $6.17 | $7.81 / $5.24 | -16.1% | +21.5% | The post-earnings drift signal suggests momentum could persist for several weeks. |
| May 29, 2026 | BUY | $5.73 | $6.36 / $4.51 | -8.9% | +31.6% | The post-earnings drift signal suggests a multi-week trend. |
| May 28, 2026 | BUY | $5.44 | — / — | +11.2% | +28.8% | The stock is exhibiting post-earnings drift, but the fundamental and technical pictures are not strongly aligned for a conviction buy. |
| May 27, 2026 | BUY | $5.29 | — / — | +5.2% | +22.4% | The stock is currently at a resistance level, and the mixed team signals warrant caution. |
| May 26, 2026 | BUY | $5.20 | — / — | +15.9% | +14.0% | The market regime is neutral, and the stock's technicals are mixed, preventing a clear directional trade. |
| May 25, 2026 | BUY | $5.20 | — / — | +15.9% | +14.0% | Post-earnings gap up and drift signal. |
| May 11, 2026 | BUY | $5.24 | — / — | -20.8% | +0.9% | Upcoming Q1 earnings date (May 11, 2026) with an EPS estimate of -0.1975. |
| May 8, 2026 | BUY | $4.82 | — / — | -21.9% | +3.4% | Upcoming clinical data for ABCL635. |
| May 7, 2026 | HOLD | $5.04 | — / — | -8.7% | +16.6% | The current market conditions and the stock's technical setup do not present a clear high-conviction opportunity for entry at this time. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.